LAUSR

We would like to share ideas on the publication ‘Evaluation of anti-nucleocapsid level variation to assess SARS-CoV-2 seroprevalence in a vaccinated population’ [1]. A novel analytical strategy was created by Bazin et al. to improve the sensitivity of illness identification in vaccine recipients [1]. The new analytical method presented herein captured a much higher proportion of immunised people with a known history of SARS-CoV-2 infection than the traditional method employed in the majority of serosurveys, according to Bazin et al. [1]. A variety of issues need to be looked at in order to fully understand the results. It is impossible to draw a connection between asymptomatic COVID-19 and the lack of symptoms without performing precise laboratory testing. Without extensive laboratory testing, asymptomatic COVID-19 and the lack of clinical symptoms could be incorrectly diagnosed. A silent COVID-19 must be ruled out if neither the most recent clinical signals nor the most recent clinical markers are present [2]. Due to further genetic variations, some individuals’ immune systems seem to react to COVID-19 differently [3]. Before the results may be validated, more clinical study is needed.